• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

Psilocybin Trial

March 1, 2022

Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada

  Achieved milestone with the start of landmark psilocybin clinical trial in Q3 2021- more than a dozen patients receive initial dose to date in first-ever Health Canada-approved, multi-dose psilocybin clinical trial in Canada Braxia Scientific funded psilocybin trial establishes psilocybin treatment framework for patients with Treatment Resistant Depression (TRD), provides patients immediate access to psychedelic treatments, and training for new therapists providing psilocybin-assisted therapy Clinics administer ~5,500 ketamine treatments to date across growing patient base in Canada   TORONTO, March 1, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal third-quarter results for the three-month period ending December 31, 2021. Complete financial statements along with related management discussion and analysis can be found...